1. bookVolume 28 (2020): Issue 1 (January 2020)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer

Published Online: 07 Feb 2020
Page range: 29 - 38
Received: 12 Aug 2019
Accepted: 30 Oct 2019
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction: The peritumoral inflammatory reaction has a substantial importance in the oncologic outcome of bladder cancer (BC). One biomarker proven to be practical and accessible is the NLR (neutrophil-to-lymphocyte ratio) for high risk non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the role of NLR as a prognostic biomarker for disease recurrence, progression and survival of p Ta (pathological assesment of the primary tumor) NMIBC.

Material and Methods: In our retrospective study we included 54 patients with pTa NMIBC from a total of 235 patients who underwent transurethral resection of bladder tumor (TURBT) during two consecutive years: January 2007 - December 2008 [median follow-up 106 months (interquartile range-IQR 68-116)]. Criteria for inclusion were: primary tumor, low-grade, with NLR available at 2 weeks prior to TURBT. NLR was considered altered if higher than 3.

Results: The median age of the patients included was 63 years (IQR 55 - 72). Most of the patients had NLR---lt---3 (37 patients). Median EORTC (European Organization of Research and Treatment of Cancer) Recurrence Score was 4 (IQR 1-6), while EORTC Progression Score was 3 (IQR 0-6), respectively. Recurrence occurred in 8 out of 54 (14.81 %) patients and progression was identified in 2 out of 54 (3.70 %) patients with muscle-invasive BC during follow-up. NLR---gt---3 was not associated with clinical and pathological factors. In multivariable Cox regression analyses NLR as a continuous variable was an independent predictive factor for recurrence. Recurrence-free survival (RFS) Kaplan-Meier analysis did not show a statistical significance between NLR groups: 82.67% vs. 64.12%, p=0.26. Kaplan-Meier analysis showed a lower Progression-free survival (PFS) in the NLR---gt---3 group: 94.12% vs. 100%, p=0.04. During follow-up (106 months) 18 patients deceased with no impact of NLR as a prognostic factor in multivariable analyses. Kaplan-Meier overall survival (OS) analysis showed a 10-year OS of 70.27% in the low NLR group compared with 58.82% in the high NLR group, p=0.45.

Conclusion: In this cohort, high NLR was associated with high recurrence rate in patients with Ta NMIBC. In low-risk NMIBC NLR could represent a valid biomarker for clinical usage regarding the intensity of follow-up schedule.

Keywords

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. DOI: 10.3322/caac.2149210.3322/caac.2149230207593Search in Google Scholar

2. Wong MCS, Fung FDH, Leung C, Cheung WWL, Gog-gins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018 18;8(1):1129. DOI: 10.1038/s41598-018-19199-z10.1038/s41598-018-19199-z577368429348548Search in Google Scholar

3. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-465; discussion 475-477. DOI: 10.1016/j.eururo.2005.12.03110.1016/j.eururo.2005.12.03116442208Search in Google Scholar

4. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi-eiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009 Nov;182(5):2195-203. DOI: 10.1016/j. juro.2009.07.016Search in Google Scholar

5. Rayn KN, Hale GR, Grave GP-L, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018 Mar;34(1):11-9. DOI: 10.4103/iju.IJU_296_1710.4103/iju.IJU_296_17576924329343907Search in Google Scholar

6. Isharwal S, Konety B. Non-muscle invasive blad-der cancer risk stratification. Indian J Urol. 2015 Dec;31(4):289-96. DOI: 10.4103/0970-1591.16644510.4103/0970-1591.166445462691226604439Search in Google Scholar

7. Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep. 2016 Sep;17(9):68. DOI: 10.1007/s11934-016-0625-z10.1007/s11934-016-0625-z498040527492610Search in Google Scholar

8. Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int. 2004 Jul;94(1):18-21. DOI: 10.1111/j.1464-410X.2003.04894.x10.1111/j.1464-410X.2003.04894.x15217424Search in Google Scholar

9. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multi-center study with central pathology review. J Urol. 2013 Jun;189(6):2069-76. DOI: 10.1016/j.juro.2012.11.12010.1016/j.juro.2012.11.12023201497Search in Google Scholar

10. Baranyi M, Lippai M, Szatmári Z. [Role of the stroma in the initiation and progression of tumors]. Orv Hetil. 2015 Nov 8;156(45):1816-23. DOI: 10.1556/650.2015.3029410.1556/650.2015.3029426522855Search in Google Scholar

11. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, et al. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan;35(1):121-30. DOI: 10.1007/s00345-016-1848-910.1007/s00345-016-1848-9523373027209168Search in Google Scholar

12. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013 Jul 23;109(2):416-21. DOI: 10.1038/bjc.2013.33210.1038/bjc.2013.332372139223799847Search in Google Scholar

13. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec;190(6):1999-2004. DOI: 10.1016/j. juro.2013.06.082Search in Google Scholar

14. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017 Mar;35(3):337-53. DOI: 10.1007/s00345-016-1826-210.1007/s00345-016-1826-227101100Search in Google Scholar

15. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, Briganti A, Roupret M, et al. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. Minerva Urol Nefrol. 2016 Aug;68(4):381-95.Search in Google Scholar

16. Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, et al. The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. Eur Urol Focus. 2016 Apr;2(1):79-85. DOI: 10.1016/j.euf.2015.03.00110.1016/j.euf.2015.03.00128723455Search in Google Scholar

17. Tang X, Du P, Yang Y. The clinical use of neutro-phil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2017 Oct;22(5):817-25. DOI: 10.1007/s10147-017-1171-510.1007/s10147-017-1171-528752351Search in Google Scholar

18. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018;73(1):111-22. DOI: 10.1016/j.eururo.2017.07.03610.1016/j.eururo.2017.07.03628867446Search in Google Scholar

19. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. Urol Oncol. 2018;36(9):389-99. DOI: 10.1016/j.urolonc.2018.05.01410.1016/j.urolonc.2018.05.01429884342Search in Google Scholar

20. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005 Apr;13(2):143-53. DOI: 10.1177/10668969050130020310.1177/10668969050130020315864376Search in Google Scholar

21. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008 Aug;54(2):303-14. DOI: 10.1016/j. eururo.2008.04.051Search in Google Scholar

22. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447-61. DOI: 10.1016/j.eururo.2016.05.04110.1016/j.eururo.2016.05.04127324428Search in Google Scholar

23. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371-80. DOI: 10.1111/bju.1376010.1111/bju.13760531560228058776Search in Google Scholar

24. Newson, R. B. (2010). Comparing the Predictive Powers of Survival Models Using Harrell’s C or Somers’ D. The Stata Journal, 10(3), 339-358. DOI: 10.1177/1536867X100100030310.1177/1536867X1001000303Search in Google Scholar

25. Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8):471-9. DOI: 10.1038/nrurol.2016.12610.1038/nrurol.2016.12627431340Search in Google Scholar

26. Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018;16(6):445-52. DOI: 10.1016/j.clgc.2018.07.00310.1016/j.clgc.2018.07.00330077463Search in Google Scholar

27. Ojerholm E, Smith A, Hwang W-T, Baumann BC, Tucker KN, Lerner SP, et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 1;123(5):794-801. DOI: 10.1002/cncr.3042210.1002/cncr.30422531987527787873Search in Google Scholar

28. Vollmer RT. A Review of Outcomes for Stage Ta Bladder Tumors. Am J Clin Pathol. 2016 Aug;146(2):215-20. DOI: 10.1093/ajcp/aqw10310.1093/ajcp/aqw10327473739Search in Google Scholar

29. Balan D, Martha O, Chibelean CB, Tataru S, Voidezan S, Sin A, et al. Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. Medicine (Baltimore). 2018 Apr;97(16):e0522. DOI: 10.1097/MD.000000000001052210.1097/MD.0000000000010522591667329668641Search in Google Scholar

30. Celik O, Akand M, Keskin MZ, Yoldas M, Ilbey YO. Preoperative neutrophil-to-lymphocyte ratio (NLR) may be predictive of pathologic stage in patients with bladder cancer larger than 3 cm. Eur Rev Med Pharmacol Sci. 2016;20(4):652-6.Search in Google Scholar

31. Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol. 2015 Feb;33(2):67.e1-7. DOI: 10.1016/j.urolonc.2014.06.01010.1016/j.urolonc.2014.06.01025060672Search in Google Scholar

32. Schulz GB, Grimm T, Buchner A, Jokisch F, Grab-bert M, Schneevoigt B-S, et al. Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Onco-logic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer. Clin Genitourin Cancer. 2017;15(6):e915-21. DOI: 10.1016/j.clgc.2017.05.00910.1016/j.clgc.2017.05.00928587816Search in Google Scholar

33. Dai J, Tang K, Xiao W, Yu G, Zeng J, Li W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3369-75. DOI: 10.7314/APJCP.2014.15.8.336910.7314/APJCP.2014.15.8.336924870724Search in Google Scholar

34. Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A, et al. Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol. 2015 Oct;141(10):1819-26. DOI: 10.1007/s00432-015-1957-710.1007/s00432-015-1957-725832016Search in Google Scholar

35. Martha O, Porav-Hodade D, Bălan D, Tătaru OS, Sin A, Chibelean CB, et al. Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer. Rev Romana Med Lab. 2017;25(2):181-9. DOI: 10.1515/rrlm-2017-001610.1515/rrlm-2017-0016Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo